CEO Total Pay
$284K
FY2023 Summary Compensation, below median
The CEO earned $284K in FY2023 against median worker pay of $284,000 · Chemicals & Pharmaceuticals.
Data updated August 2026
Subscribe to Filana Therapeutics, Inc. CEO pay filing updates (RSS)
Latest filing FY2023. This company's newest DEF 14A on file is for FY2023, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
A component-level pay breakdown is not reported in Filana Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filana Therapeutics, Inc. stamps PARITY · ELITE-MED at 1:1 against $284,000 median worker pay in FY2023. the CEO earned 1× the median employee ($284,000) in FY2023.
At $284,000 median worker pay, the PARITY stamp is near pay-parity territory under MICRO CEO total.
CEO Total Pay
$284K
FY2023 Summary Compensation, below median
Pay Ratio
1:1
Below typical
Filana Therapeutics, Inc. stamps PARITY · ELITE-MED at 1:1 against $284,000 median worker pay in FY2023. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Filana Therapeutics, Inc.'s $284K CEO total is at or below the $7.9M industry median CEO pay.
Filana Therapeutics, Inc. stamps PARITY · MICRO · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Read our methodology - how this data is sourced, computed, and verified. Filana Therapeutics, Inc. stamps PARITY · ELITE-MED at 1:1 against $284,000 median worker pay in FY2023.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps PARITY · MICRO · ELITE-MED.
ABS(ceo_total_comp) peer at $288K (Δ $4K heavier vs Filana Therapeutics, Inc.); MODEST · ELITE-MED vs this page's PARITY · MICRO · ELITE-MED.
ABS(ceo_total_comp) peer at $276K (Δ $8K lighter vs Filana Therapeutics, Inc.); MODEST · ELITE-MED vs this page's PARITY · MICRO · ELITE-MED.
ABS(ceo_total_comp) peer at $295K (Δ $11K heavier vs Filana Therapeutics, Inc.); FLOOR · ELITE-MED vs this page's PARITY · MICRO · ELITE-MED.
ABS(ceo_total_comp) peer at $298K (Δ $14K heavier vs Filana Therapeutics, Inc.); FLOOR · ELITE-MED vs this page's PARITY · MICRO · ELITE-MED.
Filana Therapeutics, Inc. stamps PARITY · MICRO · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
See where PARITY · MICRO packages sit on the national leaderboard after reading Filana Therapeutics, Inc..
Filana Therapeutics, Inc.'s PARITY stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.